In Vitro Chemoresistance and Chemosensitivity Assays
Customize your policy alerts
Sign up for Presbyterian Health Plan Policy AHS - G2100 alerts
Get alerted when Policy AHS - G2100 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of laboratory assays that test whether a patient's tumor cells are sensitive or resistant to chemotherapy drugs or drug combinations. Coverage depends on the member's benefit plan, and applicable government coverage policies take precedence when they conflict with this policy.
The policy was reviewed and updated on September 4, 2025, including the background, guidelines and recommendations, and scientific references.
CPT code 0285U was revised through an off-cycle coding modification effective July 1, 2025.
CPT code 0525U was added through an off-cycle coding modification effective January 1, 2025.
The policy was reviewed and updated on September 4, 2024, including the background, guidelines and recommendations, and scientific references.
The policy was adopted by Presbyterian Health Plan for all lines of business on January 1, 2025.
A New Mexico Medicaid link was added to the applicable state and federal regulations section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.